Table 2 Mixed effect linear regression outputs for the placebo attributable (n = 1310) and ADA attributable (n = 239) models. For training, Year was centered by subtracting 2000, Baseline CDAI was centered by subtracting 300, Age was centered by subtracting 35, BMI was centered by subtracting 20, and CRP (mg/L) was centered by subtracting 10. A. The placebo attributable model (intraclass correlation coefficient 0.02) trial random intercepts were found to be -12.808 (PRECISE1), -7.975 (UNITI1), -6.328 (CERTIFI), 6.077 (ENACT), 8.669 (ENCORE), and 12.366 (UNITI2). B. ADA attributable model (intraclass correlation coefficient 0.05) trial random intercepts were found to be -20.215 (CLASSIC), 9.439 (EXTEND), and 10.775 (NCT02499783)
Predictors | Placebo Attributable Model | ADA Attributable Model | ||||
|---|---|---|---|---|---|---|
Estimates | SE | p | Estimates | SE | p | |
Intercept | 92.18 | 13.12 | < 0.001 | 67.57 | 20.41 | 0.001 |
Year (Centered) | -1.89 | 1.55 | 0.223 | - | - | - |
Baseline CDAI (Centered) | 0.37 | 0.04 | < 0.001 | 0.12 | 0.11 | 0.276 |
Age (Centered) | 0.13 | 0.21 | 0.549 | -1.77 | 0.57 | 0.002 |
BMI (Centered) | 0.52 | 0.54 | 0.341 | -1.45 | 1.34 | 0.28 |
CRP (mg/L) (Centered) | -0.28 | 0.11 | 0.012 | -0.35 | 0.28 | 0.213 |
Sex: Male | -0.72 | 5.17 | 0.889 | 7.14 | 12.13 | 0.556 |
History of TNFi Use | -37.56 | 6.32 | < 0.001 | 7.51 | 20.38 | 0.712 |
Steroid Use | 7.15 | 5.24 | 0.172 | 5.36 | 14.35 | 0.709 |
Immunomodulator Use | 5.42 | 5.45 | 0.32 | -17.43 | 12.54 | 0.164 |
Ileal Disease | -7.46 | 5.99 | 0.213 | 2.84 | 13.74 | 0.836 |